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Purpose: To evaluate the long-term safety of polyethylene glycol 
(PEG) 4000 in children with constipation, particularly the biochemical 
aspects of safety. 
Methods: Medical records were evaluated, and 100 children, who 
had been taking PEG 4000 for more than 6 months, and who had 
been under clinical and biochemical monitoring, were enrolled. Ages; 
6.11±3.12 years, Duration of therapy; 16.93±7.02 months, dose of PEG 
4000; 0.72±0.21 g/kg/d. 
Results: None of the children complained of clinical adverse effect. 
The first biochemical test was performed at 8.05 months after 
beginning of PEG 4000. Serum phosphate (SP) value was high in 10 
children, and leucopenia was noted in one child. The second test was 
performed in 44 children at 7.57 months after the first test. The SP 
value was high in four children, including the three children whose 
initial SP value was high and one new child. Six out of 10 children with 
high initial SP value became normal and one was lost. Hypernatremia 
was noted in one child. The third test was done in 15 children at 7.5 
months after the second test. The SP value of the new child from the 
second test was high, but became normal after finishing treatment. 
Two out of 3 children with high SP value at the second test became 
normal and one was lost. The fourth test was done in 2 children few 
months after the third test. All of the results were normal. There were 
no relation between duration of therapy and hyperphosphatemia, or 
between dose of PEG 4000 and hyperphosphatemia. 
Conclusions: PEG 4000 is safe for long-term therapy in children with 
constipation with respect to biochemical parameters. 
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Introduction
Various medications can be applied to children with chronic 
constipation, and lactulose/sorbitol, mineral oil, and magnesium 
hydroxide have been  considered to be safe for long-term use in 
children
1-3).  Recently, polyethylene glycol (PEG) products for 
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children gained in public favor. PEG 3350 solution with electrolytes 
was introduced for colonoscopic preparation in the late 1990’s, and 
for disimpaction in children with chronic constipation
4, 5). However, 
use of a large amount of PEG 3350 solution with electrolytes   
imposes some limitations, given its awful taste and potential risk 
for causing electrolyte imbalance in children. Recently, PEG 
products without electrolytes have been introduced for children 
with constipation in order to overcome the problems of PEG with 
electrolytes
6-11). 
Concern about the long-term safety of PEG without electrolytes 
products in children with chronic constipation is one of the 
most important issues now. However, there are very few studies 
on the long-term safety of PEG products without electrolytes in 
children with chronic constipation that address both  clinical and 
biochemical aspects. Those studies that have been performed are 
mainly on PEG 3350 from North America, and the duration of 
the studies is about one year
6, 7, 11-13), while studies of PEG 4000 are 
even rarer and the duration of the latter studies is not long
8-10, 14). In 
the present study, the long-term safety of PEG 4000 was evaluated 
with a large number of children and for a long time, focusing on the 
biochemical aspect of treatment safety. 
Materials and methods
 Medical records were evaluated {350 children, 153 boys, 197 
girls, mean age 8.43±4.56 yr (2-19)} and children who had been 
taking PEG 4000 (Forlax
®, Beaufour Ipsen Pharma., Paris, 
France) for more than 6 months, under the diagnosis of chronic 
constipation of ROME III criteria
15), between  July, 2007 and 
March, 2010 at Konkuk University Hospital, and who had been 
under clinical and biochemical monitoring, were enrolled. One 
hundred of children (50 boys, 50 girls) were enrolled in this study. 
Their ages were 6.11±3.12 years (2-17 years), and the duration of 
the therapy was 16.93±7.02 months (7-46 months) and the initial 
maintenance dose of PEG was 0.72±0.21 g/kg/d (0.18-1.14 g/kg/d) 
(Table 1).
The compliance and effect of medication were guaranteed with 
defecation diary which was kept by the patient or guardian. The 
children had been under clinical monitoring (urticaria, diarrhea, 
nausea, abdominal pain, headache, dizziness, tingling sensation, 
convulsion, change in consciousness)
16-18), and biochemical 
monitoring, such as, complete blood count with reticulocyte, liver 
function test, glucose, blood urea nitrogen, creatinine, calcium, 
phosphate, electrolytes (including tCO2) and serum osmolality, per 
several months. 
The relations between duration of therapy and hyperphospha-
temia, and between  dose of PEG 4000 and hyperphophatemia 
were evaluated with Student’s t-test. 
Results
During therapy, none of the children complained of clinical 
symptoms associated with PEG, such as urticaria, diarrhea, 
abdominal pain, headache, dizziness, numbness, seizure, or change 
of consciousness. 
One hundred children underwent biochemical testing more 
than once. The first biochemical test was performed at 8.05±2.50 
(4-16 months) after the beginning of the PEG 4000. Serum 
phosphate values were more than 6.0 mg/dL in 10 children, and 
leucopenia was noted in one child. The second test was performed 
in 44 children at 7.57±2.29 (4-15 months) after the first test. The 
serum phosphate value was more than 6.0 mg/dL in four children, 
including the three children with a high initial phosphate value and 
one new child. Six out of 10 children whose initial phosphate values 
were high became normal and one was lost. Serum sodium value 
was high in one child (146 mMol/L). The third test was done in 15 
children at 7.27±1.53 (5-10 months) after the second test. Serum 
phosphate value of the new child from the second test was high, 
but became normal after finishing 2 more months of treatment. 
Two out of 3 children with high phosphate value at the second test 
became normal and one was lost. The fourth test was done in 2 
children at 2-7.5 months after the third test. All of the results were 
normal (Fig. 1, Table 2). 
Overall, 10% (11/100) of children who have been treated 
with PEG 4000 for more than 6 months experienced 
Table 1. The Demographic Features of the Children
Characteristics Number  (n=100)
Sex
  Male
  Female
Age (yr)
  2-5
  6-10
  11-18
Dose of PEG 4000 (g/kg/d)
  0.10-0.39
  0.40-0.69
  0.70-1.10
Duration of therapy (mo.)
  6-12
  13-18
  19-24
  25-35
  36-48
50
50
55
36
  9
10
31
59
29
34
25
10
  2
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hyperphosphatemia during therapy. However, significant clinical 
problems were not noted in children with hyperphosphatemia.
The relations between duration of therapy and hyperpho-
sphatemia (P=0.738), and between dose of PEG 4000 and 
hyperphosphatemia (P=0.384), were not statistically significant. 
Discussion
Generally, the duration of treatment for functional constipation 
is considered to be 6 to 24 months
3). Considering a long duration 
of therapy, the safety of the medicine is more important than the 
efficacy of the medication, when the pediatrician selects a drug for 
functional constipation in children. Lactulose/Sorbitol, mineral oil, 
magnesium hydroxide, and PEG have been considered to be safe 
for long-term use in children
1-3). Furthermore, fiber can be included 
in this category, on the basis of theoretical consideration. 
Lactulose and Sorbitol are non-absorbable disaccharides, 
and both are easily taken by children, although lactulose is 
contraindicated in children with galactosemia. Mineral oil is the 
most commonly used of the lubricant laxatives. A major concern 
about the long-term use of mineral oil has been that it may interfere 
with absorption of the fat-soluble vitamins. However, two studies 
have dismissed this concern
19, 20). Magnesium hydroxide is the most 
commonly used magnesium salt. It can cause hypermagnesemia, 
hypophosphatemia, secondary hypocalcemia and volume overload 
in children with renal insufficiency and in young infants. 
A few pediatric studies with PEG 3350 have revealed clinical 
side effects such as atopy, nausea, vomiting, and abdominal pain
6, 
7, 11-13). In one study with PEG 3350, biochemical follow-up was 
performed for 12 months, and mild elevation of AST was noted in 
some children
12). A pediatric clinical study with PEG 4000 that was 
performed in France for 3 months revealed no significant problems 
clinically
8), or biochemically
14).   
In the present study, 100 children were enrolled and the mean 
duration of treatment was about 17 months (7-46 months).   
Significant clinical problems were not noted during observation. 
Many biochemical parameters were analyzed, and the serum 
phosphate level was elevated in some children. Generally, serum 
phosphate increases in cases of acute, chronic renal failure, 
aggravated catabolic stress, lactic acidosis, hypocalcemia, 
cytolysis during chemotherapy, administration of a large 
quantity of phosphate, or hypoparathyroidism
21). In the present 
study, the etiology of hyperphosphatemia remains unclear, and 
hyperphosphatemia resolved spontaneously despite continuance 
of treatment except in one child. Although the major human 
adverse event related to high PEG exposure is renal toxicity (acute 
renal tubular necrosis)
22), the relationship between PEG 4000 
at therapeutic dose (0.25-1.0 g/kg/d) and hyperphosphatemia 
warrants further study. 
In pediatric studies with PEG 3350, mild elevation of AST 
was reported
12). However, this phenomenon was not noted in the 
present study. 
PEG 4000 is safe for long-term therapy in children with chronic 
constipation in terms of biochemical parameters. However, 
pediatricians are in need of biochemical follow-up, especially for 
serum phosphate.   
100 (M 50, F 50)
Age : 6.11±3.12 yr. (2-17)
Duration of Therapy : 16.93±7.02 Mo. (7-46)
Dose of PEG 4000 : 0.72±0.21 g/kg/d (0.18-1.14)
100 Children
44 Children
15 Children
2 Children
Biochemical
Test
CBC, reticulocyte, 
Ca/P, BUN/Cr, TP/Alb., 
AST/ALT, Glu., Uric 
acid, TB, S-AP, S-E’ 
(including tCo2), 
S-Osm.
Clinical Status
1st
2nd
3rd
4th
Hyperphosphatemia : 10
Leukopenia : 1
Hyperphosphatemia : 4
S-Na : 146 mMol/L : 1
Hyperphosphatemia : 1 
WNL
8.05±2.50 (4-16 Mo.)
7.57±2.29 (4-15 Mo.)
7.27±1.53 (5-10 Mo.)
2-7 Mo.
Fig. 1. Overall flow of the study. During polyethylene glycol (PEG) 
4000 treatment for constipation in children, biochemical testing was 
performed serially. Hyperphosphatemia developed in some children, but 
most resolved spontaneously despite continuance of treatment except 
in one child. Abbreviations: CBC, Complete blood count; Ca, Calcium: 
P, Phosphorus; BUN, Blood urea nitrogen; Cr, Creatinine; TP, Total 
protein; Alb, Albumine; AST/ALT,  Aspartate aminotransferase/Alanine 
aminotransferase; Glu, Glucose; TB, Total bilirubin; S-AP, Serum alkaline 
phosphatase; S-E’, Serum electrolytes; S-Osm, Serum osmolarity.
Table 2. The Change of Serum Phosphate Levels in Children with 
Hyperphosphatemia during PEG* 4000 Treatment for Constipation
Patients
(Sex/Age)
Serum Phosphate Level (mg/dL) Duration  of
Treatment (Mo.) Base 1
st  Test 2
nd Test 3
rd Test 4
th Test
1 (M/4)
2 (F/6)
3 (M/6)
4 (M/5)
5 (F/9)
6 (F/17)
7 (M/3)
8 (M/5)
9 (F/6)
10 (M/5)
11 (M/4)
 5.7
 6.1
 5.8
 5.4
 5.5
 5.0
 5.0
 5.6
 4.6
 5.3 
 5.6
6.1
6.6
6.4
6.1
6.3
6.0
6.0
6.0
6.3
6.4
5.5
6.6
6.4
6.1
4.8
5.2
4.5
5.4
5.4
5.0
Loss
6.2
5.4
5.5
Loss
6.3 5.0
16
17
18
20
26
14
13
19
 21
18
18 
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